U.S. Food and Drug Administration (FDA) has approved a new drug (simeprevir) to treat patients suffering from chronic form of hepatitis C.
Hepatitis C virus can target the liver and causes inflammation that could lead to liver failure and death as well. Most of the patients with hepatitis C remain asymptomatic unless the liver damage becomes prominent and significant. Such patients may suffer different sign and symptoms such as;
- Nausea , vomiting
- Muscle aches
- Lack of appetite
- Abdominal pain
- Scarring in the liver (cirrhosis)
It has been estimated by Centre for Disease Control and Prevention (CDC) that nearly 3.2 million people in US are suffering from Hepatitis C.
Olysio (simeprevir) mainly prevent the replication of the hepatitis C virus by blocking the protein that is necessary for viral proliferation. FDA has recommended the use of Olysio in certain conditions including;
Those patients who have damaged liver but their liver is functioning and no treatment has yet been started,
Those patients who have damaged liver and are unable to get significant therapeutic benefit from previous drug therapy.
Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
Some common adverse events associated with Olysio are as follows;
- Itching and etc.
Source: FDA News Release
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.